VR Logo

Oragenics Inc. (OGEN) download report


Healthcare | Biotechnology & Pharma Research

Oragenics Inc. (OGEN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

IPO Date: 25-Feb-2004

Exec. Chairman: Dr. Frederick W. Telling Ph.D.

CFO, Sec., Treasurer & Interim Principal Exec. Officer: Mr. Michael O. Sullivan CPA

Listing: NYSE: OGEN

Country: United States

Headquarters: Tampa, FL

Website: https://www.oragenics.com

Key Facts

Market cap: $38.91 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-16.53 Mln

Cash: $21.37 Mln

Total Debt: $0.57 Mln

Insider's Holding: 3.90%

Liquidity: Low

52 Week range: $0.22 - 1.15

Shares outstanding: 116,395,000

10 Years Aggregate:

  • CFO: $-88.59 Mln
  • EBITDA: $-129.04 Mln
  • Net Profit: $-128.03 Mln

Stock Performance

Time Period Oragenics (OGEN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-25.71-8.62-18.78
1 month1.30-4.54-8.00
3 months-1.68-10.19-13.65
1 Year-52.921.43-17.19
3 Years-11.9710.146.10
5 Years-38.1711.265.87
10 Years-34.9111.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Oragenics (OGEN) S&P Small-Cap 600 S&P BSE Sensex
20210.2225.2721.99
2020-14.159.5715.75
2019-39.1020.8614.38
2018-63.24-9.705.87
2017-56.5011.7327.91
2016-64.0024.741.95
201568.60-3.36-5.03